TRIZIVIR - abacavir sulfate, lamivudine, and zidovudine
Navigation: NDC > Supplier starting with: V > VIIV HEALTHCARE COMPANY| Field | Value |
|---|---|
| NDC Code: | 49702-217 |
| Proprietary Name: | TRIZIVIR |
| Suffix: | |
| Non-Proprietary Name: | abacavir sulfate, lamivudine, and zidovudine |
| Dosage Form: | TABLET, FILM COATED |
| Method: | ORAL |
| Original Marketing Date: | 02-11-2010 |
| Category Name: | NDA |
| Application Number: | NDA021205 |
| Labeler: | VIIV HEALTHCARE COMPANY |
| Substance Name: | ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE |
| Active Numerator Strength: | 300; 150; 300 |
| Active Ingredient Unit: | mg/1; mg/1; mg/1 |
| Pharm Classes: | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| DEA Schedule: |